Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Saturday's Featured Content 2 Small-Cap Biotechs That Could Reward Patient InvestorsBy Chris Markoch. Date Posted: 12/12/2025. 
At a Glance - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Nevertheless, if you're considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and have no commercially available drugs or therapeutics. That also means they typically report negative earnings (i.e., are not profitable) and have little to no revenue. Success often hinges on the outcome of a single clinical-stage candidate. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> Even if a product advances through trials, profitability can still be years away. Only after reaching that milestone do companies typically attract analyst coverage and institutional investment. Yet getting into one of these medical stocks before it "hits" can pay off handsomely. In an instant, investors could see 3x, 5x, or even 10x returns — while others may never pan out. That's why many penny-stock investors spread a lump sum across multiple biotech names; if it's a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed has a commercially available product: ColoAlert — the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany's digital-health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is substantial. Mainz Biomed is also developing a non-invasive, blood-based screening test for early detection of pancreatic cancer. The company reported positive topline results in October, but commercialization remains years away. Risks are substantial: ColoAlert is not yet available in the United States, and despite early European sales and plans to expand into South America, revenue remains minimal. The company included “Going Concern” language in its Sept. 26 SEC filing and has since filed a $150 million mixed shelf offering. For now, that may be enough to keep MYNZ above $1 and avoid a delisting notice. Mainz Biomed is racing to generate meaningful revenue — if successful, even a small stake could deliver a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive antiviral approach, but it also carries significant financial risk that speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary "nanoviricide" platform. These candidates are designed to mimic human cell surfaces, luring viruses to bind and thereby neutralizing them before they can infect real cells. It's an innovative concept that, if validated in human trials, could represent a new approach to treating infectious diseases. NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has produced encouraging preclinical data suggesting strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to advance its programs. The company reported limited cash on hand in recent filings, so investors should expect the possibility of future dilution. Still, if even one candidate advances successfully into clinical development, the valuation upside could be substantial. For patient, high-risk investors, NNVC represents a genuine moonshot in the antiviral space.
| 
